Related Experiment Video
Updated: May 7, 2026
Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
Free circulating DNA as a biomarker of prostate cancer: comparison of quantitation methods
Kavitha Ramachandran1, Carl G Speer, Stephanie Fiddy
1Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave, Miami, FL-33136, U.S.A. rsingal@med.miami.edu.
Aim:
To identify a simpler method of free circulating DNA (fcDNA) quantitation that may improve the specificity of the prostate cancer prostate-specific antigen (PSA) screening test.
Materials And Methods:
The patient group consisted of 241 men with elevated PSA/abnormal digital rectal exam (DRE), undergoing prostate biopsy. Serum fcDNA levels were measured by UV absorbance and PicoGreen. Results were compared to previously published quantitative polymerase chain reaction (qPCR) data.
Results:
We found that levels of fcDNA measured by PicoGreen correlated well with those measured by qPCR (r=0.8552). In the patient group with PSA >4 to 10 ng/ml, those with fcDNA (PicoGreen) >53.1 ng/ml were at increased risk for prostate cancer compared to those with fcDNA ≤ 53.1 ng/ml. Moreover, we found that measuring fcDNA levels by PicoGreen does not compromise the negative predictive value, accuracy or specificity of the qPCR fcDNA test.
Conclusion:
If validated in larger studies, PicoGreen quantitation of fcDNA could serve as a simple method to aid in prostate cancer diagnosis.
